Riverbridge Partners LLC Buys 11,129 Shares of LeMaitre Vascular, Inc. $LMAT

Riverbridge Partners LLC grew its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 12.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 99,596 shares of the medical instruments supplier’s stock after purchasing an additional 11,129 shares during the quarter. Riverbridge Partners LLC’s holdings in LeMaitre Vascular were worth $8,226,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of LMAT. Summit Creek Advisors LLC lifted its stake in LeMaitre Vascular by 0.9% in the 3rd quarter. Summit Creek Advisors LLC now owns 49,624 shares of the medical instruments supplier’s stock valued at $4,098,000 after buying an additional 450 shares in the last quarter. Kornitzer Capital Management Inc. KS boosted its holdings in LeMaitre Vascular by 11.0% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 13,650 shares of the medical instruments supplier’s stock worth $1,127,000 after buying an additional 1,352 shares during the last quarter. Boston Trust Walden Corp purchased a new stake in LeMaitre Vascular during the 3rd quarter worth approximately $28,546,000. Bridge City Capital LLC increased its stake in LeMaitre Vascular by 35.5% during the 3rd quarter. Bridge City Capital LLC now owns 116,980 shares of the medical instruments supplier’s stock worth $9,661,000 after buying an additional 30,639 shares in the last quarter. Finally, ProShare Advisors LLC increased its stake in LeMaitre Vascular by 36.2% during the 3rd quarter. ProShare Advisors LLC now owns 102,571 shares of the medical instruments supplier’s stock worth $8,471,000 after buying an additional 27,270 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Down 2.6%

NASDAQ LMAT opened at $79.02 on Wednesday. LeMaitre Vascular, Inc. has a 52 week low of $78.22 and a 52 week high of $118.01. The company has a quick ratio of 12.54, a current ratio of 14.60 and a debt-to-equity ratio of 0.39. The business’s fifty day simple moving average is $81.47 and its 200-day simple moving average is $94.05. The firm has a market cap of $1.81 billion, a PE ratio of 29.51, a P/E/G ratio of 2.39 and a beta of 0.51.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.04). LeMaitre Vascular had a net margin of 23.51% and a return on equity of 15.33%. The firm had revenue of $67.97 million for the quarter, compared to analyst estimates of $67.39 million. During the same period in the previous year, the firm posted $0.75 EPS. The company’s revenue was up 11.3% compared to the same quarter last year. As a group, equities analysts anticipate that LeMaitre Vascular, Inc. will post 2.83 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Thursday, November 19th will be paid a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, November 19th. This represents a $1.00 dividend on an annualized basis and a yield of 1.3%. LeMaitre Vascular’s payout ratio is 36.36%.

Analysts Set New Price Targets

LMAT has been the subject of a number of research analyst reports. Wells Fargo & Company reduced their target price on LeMaitre Vascular from $94.00 to $86.00 and set an “equal weight” rating for the company in a report on Thursday, November 5th. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Citizens Jmp initiated coverage on LeMaitre Vascular in a research note on Thursday, November 5th. They issued a “market outperform” rating and a $110.00 price target on the stock. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $108.25.

About LeMaitre Vascular

LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.